On-target, off-tumor toxicities of ADCs can become dose-limiting in the clinic when choosing targets with low-to-moderate expression levels on normal tissues, such as TROP2, Epithelial cell adhesion molecule (EpCAM), and EPH receptor A2 (EphA2). This evidence concerns the gene TACSTD2 and neoplasm.